SWOT Analysis for Aurobindo Pharma Ltd.

Benjamin Graham Value Screen
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Companies with Low Debt
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
RSI indicating price strength
High Volume, High Gain
Stocks in uptrend most likely to cross above SMA-200 soon
Top Gainers
Volume Shockers

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

RSI indicating price strength

High Volume, High Gain

Stocks in uptrend most likely to cross above SMA-200 soon

Top Gainers

Volume Shockers

Promoters increased pledged shares QoQ
Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)
High promoter stock pledges
Highest increase in pledges by promoters
Stocks Underperforming their Industry Price Change in the Quarter

Promoters increased pledged shares QoQ

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

High promoter stock pledges

Highest increase in pledges by promoters

Stocks Underperforming their Industry Price Change in the Quarter

Brokers upgraded recommendation or target price in the past three months
Mutual Funds Increased Shareholding in Past Month
Big Deal (Insider and SAST) buys last month greater than 1% of total shares
Street Favorite: High Analyst Rating with at least 20% upside
MFs increased their shareholding last quarter
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months

Brokers upgraded recommendation or target price in the past three months

Mutual Funds Increased Shareholding in Past Month

Big Deal (Insider and SAST) buys last month greater than 1% of total shares

Street Favorite: High Analyst Rating with at least 20% upside

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Recent Broker Downgrades in Reco or Target Price
US FDA Warning Letter
Red Flag: Companies seeing significant coronavirus impact

Recent Broker Downgrades in Reco or Target Price

US FDA Warning Letter

Red Flag: Companies seeing significant coronavirus impact

Indian stocks that could be impacted by Brexit (Britain leaving the EU)
Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Decline in Net Profit with falling Profit Margin (QoQ)

Indian stocks that could be impacted by Brexit (Britain leaving the EU)

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)

Aurobindo Pharma Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Aurobindo Pharma Ltd. has 18 Strengths, 5 Weaknesses, 7 Opportunities and 3 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Benjamin Graham Value Screen

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

PEG lower than Industry PEG

Stocks gaining versus previous close, open price and RSI

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Companies with Low Debt

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

RSI indicating price strength

High Volume, High Gain

Stocks in uptrend most likely to cross above SMA-200 soon

Top Gainers

Volume Shockers

Promoters increased pledged shares QoQ

Degrowth in Revenue, Profits and Operating Profit Margin in recent results (QoQ)

High promoter stock pledges

Highest increase in pledges by promoters

Stocks Underperforming their Industry Price Change in the Quarter

Brokers upgraded recommendation or target price in the past three months

Mutual Funds Increased Shareholding in Past Month

Big Deal (Insider and SAST) buys last month greater than 1% of total shares

Street Favorite: High Analyst Rating with at least 20% upside

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Recent Broker Downgrades in Reco or Target Price

US FDA Warning Letter

Red Flag: Companies seeing significant coronavirus impact

Indian stocks that could be impacted by Brexit (Britain leaving the EU)

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Net Profit with falling Profit Margin (QoQ)